ClinicalTrials.gg
CompletedNCT04326660SCOPEUpdated Nov 10, 2026

SCOPE-Chinese Women Study

An interventional study of SCOPE-Chinese Women in Cancer, Breast and Obesity, Abdominal, sponsored by University of California, San Francisco. Completed at 2 sites in 2 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention

How we know

Updated Nov 10, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Enrollment
13th of 49
102 · median 38
Started
2020
with 2 others
No phase
23 of 62
4 open now
Registered
45th of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 13th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 with no phase, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This project examines the feasibility of a smartphone-based intervention to reduce obesity and breast cancer risk among Chinese women in China. The proposed intervention is to use the mobile application and an activity tracker device to promote a healthier lifestyle and physical activity. The intervention will be tailored to the participants' behaviors, personal needs, and preferences. The aim is to reduce abdominal obesity and improve healthy lifestyle behaviors in premenopausal women with children in order to reduce the growing cancer burden in China.

Read the detailed description

Cancer presents a major disease burden across the globe. The incidence and mortality of gynecologic cancers have increased significantly in China over the last two decades with breast and endometrial cancer as leading causes of death in women in China. Obesity, especially abdominal obesity, and unhealthy lifestyles are major risk factors for breast and endometrial cancer. A high risk group for obesity is mothers with dependent children as they have high levels of stress and family responsibilities that prevent regular engagement in a healthy lifestyle and early screening activities. Because reducing postmenopausal abdominal obesity is very difficult and because of the significant increased risk for gynecologic cancers in obese postmenopausal women, interventions that aim to reduce abdominal obesity and improve healthy lifestyle behaviors in premenopausal women with children are critical to reducing the growing cancer burden in China. A smartphone-based intervention provides a promising platform for obesity and cancer prevention. In this proposed study, the research team will modify the Healthy Mothers Healthy Children: Technology-Based Intervention to Prevent Obesity, which was developed by the principal investigator. The proposed intervention (titled "The Smartphone-Based Cancer and Obesity Prevention Education Program for Chinese Women: SCOPE-Chinese Women") is a smartphone-based, data-driven, and individually tailored intervention. It includes 12 weekly educational modules and six bi-weekly tailored messages delivered via WeChat, a popular communication app in China. The intervention will also be tailored to the participants' behaviors, personal needs, and preferences. The overall goal of this proposed study is to assess the feasibility and estimate the preliminary efficacy of the SCOPE-Chinese Women intervention using a randomized control study design (RCT). The following aims will be addressed.

Aim 1: To assess the feasibility of the smartphone-based lifestyle intervention (i.e., SCOPE-Chinese Women).

Aim 2: To estimate the preliminary efficacy of the SCOPE-Chinese Women intervention on the primary outcome (waist circumference) and secondary outcomes (body mass index, self-efficacy, food intake, physical activity, and metabolic risk) between the intervention and control groups at baseline, 3 months, and 6 months.

Aim 3: To understand participants' acceptance, barriers to adherence, and recommendations for intervention.

03

Conditions studied

  • Cancer, Breast
  • Obesity, Abdominal

Keywords

  • Obesity
  • Abdominal
  • Cancer Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must:

  • Be female
  • Be at least 18 years old
  • Have a waist circumference great than 80 cm
  • Own a smartphone
  • Be able to read Chinese and speak Mandarin
  • Be premenopausal
  • Have a child between the age of 1 and 18 years old

Exclusion criteria

Exclusion Criteria:

Women are excluded from the study if they:

  • Are pregnant
  • Gave birth less than 12 months prior to enrollment date
  • Have an acute or life-threatening disease (e.g., renal failure).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • No intervention
    Control

    Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.

  • Experimental
    SCOPE-Chinese Women Intervention

    SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention. Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant. Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total. Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences.

    Other: SCOPE-Chinese Women

Interventions

  • OtherSCOPE-Chinese Women

    SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.

06

What researchers measure

Primary outcomes

  1. Mean Change in Waist Circumference Over Time

    The National Institutes of Health (NIH) waist circumference measurement protocol will be used to measure change in waist circumference for each participant over time.

    Time frame: Baseline, 3 months, and 6 months

Secondary outcomes

  1. Mean Change in Body Mass Index (BMI) Over Time

    Weight and height will be used to compute the BMI with the formula=weight (kilograms(kg)) / height in (meters squared (m2). Changes in BMI will be collected for each participant over time.

    Time frame: Baseline, 3 months, and 6 months

  2. Mean Change in Scores on the Self-Rated Abilities for Health Practices Scale Over Time

    The Self Rated Abilities for Health Practices Scale (SRAHP) is a 28-item survey, with each item scored on a 5-point scale, with item scores ranging from 0=Not at all to 4=Completely. The survey is designed to measure self-perceived ability to implement health-promoting behaviors across four subscales: Exercise, Nutrition, Responsible Health Practice, and Psychological Well Being, and overall. The total score ranges from 0 - 112, with higher scores indicating greater abilities for health practices. Changes in scores will be collected for each participant over time.

    Time frame: Baseline, 3 months, and 6 months

  3. Mean Changes in China Food Frequency Questionnaire (FFQ) over time.

    Food intake using the China food frequency questionnaire (FFQ), which includes a list of 118 food items will be used to measure aggregate changes in food intake over time.

    Time frame: Baseline, 3 months, and 6 months

  4. Mean Changes in Overall Physical Activity

    Change in overall Physical activity over time will be measured using the Fitbit Alta-HR device for 10 hours while participants are awake.

    Time frame: Baseline, 3 months, and 6 months

  5. Mean Change in Blood Pressure Over Time

    Changes in blood pressure will be measured using the YuWell YE690A monitor for each participant over time.

    Time frame: Baseline, 3 months, and 6 months

  6. Mean Change in Hemoglobin A1C (HbA1C) Over Time

    A blood sample will be collected to measure change in HbA1C over time for each participant, using an established cut off value at 6.4%.

    Time frame: Baseline and 6 months

  7. Mean Change in Serum Lipid Levels Over Time

    A blood sample will be collected to measure change in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides (all measured in milligrams per deciliter (mg/dL)) over time for each participant

    Time frame: Baseline and 6 months

  8. Mean Change in Cortisol over time

    A blood sample will be collected to measure change in total cortisol levels over time for each participant.

    Time frame: Baseline and 6 months

  9. Relative telomere length (RTL)

    A blood sample will be collected to measure relative telomere length (RTL), assessed using the real-time quantitative polymerase chain reaction (qPCR) technique, adhering to the protocol specified by Cawthon.

    Time frame: baseline and 6 months follow-up.

Other outcomes

  1. Percentage of Eligible participants Who Agree To Be Screened

    The number of overall eligible participants and the number of eligible participants who agree to be screened will be used to compute the percentage used for enrollment.

    Time frame: At Baseline

  2. Number of Uses of The Tracking App Over Time

    The number of uses of the tracking app and frequency of accessing the 12 modules, to measure change in usability over time

    Time frame: Baseline to 6 months

  3. Percentage of Participants who completed assessments

    The percentage of completed assessments by participants at each visit will be used to measure adherence over time

    Time frame: Up to 6 months

07

Study locations

2 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Central South University
    Yuelucun, Changsha, Hunan 410083, China
08

References and documents

Publications

  • Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014 Jun;15(7):e279-89. doi: 10.1016/S1470-2045(13)70567-9. PubMed 24872111 ↗
  • Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2018 Jan;29(1):e7. doi: 10.3802/jgo.2018.29.e7. PubMed 29185265 ↗
  • Fair AM, Dai Q, Shu XO, Matthews CE, Yu H, Jin F, Gao YT, Zheng W. Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect Prev. 2007;31(3):214-9. doi: 10.1016/j.cdp.2007.04.003. Epub 2007 Jul 23. PubMed 17646056 ↗
  • Wang X, Li L, Gao J, Liu J, Guo M, Liu L, Wang W, Wang J, Xing Z, Yu Z, Wang X. The Association Between Body Size and Breast Cancer in Han Women in Northern and Eastern China. Oncologist. 2016 Nov;21(11):1362-1368. doi: 10.1634/theoncologist.2016-0147. Epub 2016 Aug 5. PubMed 27496041 ↗
  • Cutrona CE, Abraham WT, Russell DW, Beach SR, Gibbons FX, Gerrard M, Monick M, Philibert R. Financial strain, inflammatory factors, and haemoglobin A1c levels in African American women. Br J Health Psychol. 2015 Sep;20(3):662-79. doi: 10.1111/bjhp.12120. Epub 2014 Oct 18. PubMed 25327694 ↗
  • Landstedt E, Harryson L, Hammarstrom A. Changing housework, changing health? A longitudinal analysis of how changes in housework are associated with functional somatic symptoms. Int J Circumpolar Health. 2016 Jun 30;75:31781. doi: 10.3402/ijch.v75.31781. eCollection 2016. PubMed 27369590 ↗
  • Berge JM, Larson N, Bauer KW, Neumark-Sztainer D. Are parents of young children practicing healthy nutrition and physical activity behaviors? Pediatrics. 2011 May;127(5):881-7. doi: 10.1542/peds.2010-3218. Epub 2011 Apr 11. PubMed 21482603 ↗
  • Liu Y, Warren Andersen S, Wen W, Gao YT, Lan Q, Rothman N, Ji BT, Yang G, Xiang YB, Shu XO, Zheng W. Prospective cohort study of general and central obesity, weight change trajectory and risk of major cancers among Chinese women. Int J Cancer. 2016 Oct 1;139(7):1461-70. doi: 10.1002/ijc.30187. Epub 2016 May 31. PubMed 27177094 ↗
  • Sun A, Cheng J, Bui Q, Liang Y, Ng T, Chen JL. Home-Based and Technology-Centered Childhood Obesity Prevention for Chinese Mothers With Preschool-Aged Children. J Transcult Nurs. 2017 Nov;28(6):616-624. doi: 10.1177/1043659617719139. Epub 2017 Jul 8. PubMed 28826348 ↗
  • Guan X, Sun G, Zheng L, Hu W, Li W, Sun Y. Associations between metabolic risk factors and body mass index, waist circumference, waist-to-height ratio and waist-to-hip ratio in a Chinese rural population. J Diabetes Investig. 2016 Jul;7(4):601-6. doi: 10.1111/jdi.12442. Epub 2015 Dec 26. PubMed 27181937 ↗
  • Wen X, Mai J, Gao X, Guo M, Wu Y, Liu X, Zhao L. [Cut-off values of waist circumference for central obesity in Chinese adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2015 Sep;43(9):822-6. Chinese. PubMed 26652826 ↗
  • Nanayakkara J, Lekamwasam S. Validity of BMI, hip and waist circumferences as surrogate measures of obesity in a cohort of Sri Lankan premenopausal women. Ceylon Med J. 2013 Jun;58(2):72-5. doi: 10.4038/cmj.v58i2.4720. PubMed 23817937 ↗
  • Singhal N, Mathur P, Pathak R. Validity of simple, novel measures of generalized and central obesity among young Asian Indian women. Indian J Med Sci. 2011 Dec;65(12):518-27. PubMed 23548252 ↗
  • Yu R, Yan LL, Wang H, Ke L, Yang Z, Gong E, Guo H, Liu J, Gu Y, Wu Y. Effectiveness of a community-based individualized lifestyle intervention among older adults with diabetes and hypertension, Tianjin, China, 2008-2009. Prev Chronic Dis. 2014 May 15;11:E84. doi: 10.5888/pcd11.120333. PubMed 24831288 ↗
  • Zhang R, Li Y, Zhang S, Cai X, Zhou X, Ji L. The Association of Retinopathy and Plasma Glucose and HbA1c: A Validation of Diabetes Diagnostic Criteria in a Chinese Population. J Diabetes Res. 2016;2016:4034129. doi: 10.1155/2016/4034129. Epub 2016 Oct 11. PubMed 27807545 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2022, 29 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 29 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2021 → Dec 2022 and completion Dec 2021 → Dec 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 30, 2020
StartActual
Jul 20, 2020
Primary completionActual
Dec 30, 2022was Dec 2021
CompletionActual
Dec 30, 2022was Dec 2021
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Central South University · Yuelucun, China
Show 1 removed
  • Central South University · Yuelu, China
Nov 10, 2026
Primary completion
Dec 30, 2021→Dec 30, 2022
Nov 10, 2026
Study completion
Dec 30, 2021→Dec 30, 2022
Nov 10, 2026
Enrollment
40→102
Nov 10, 2026
Eligibility
Revised
Nov 10, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedRelative telomere length (RTL)Time frame: baseline and 6 months follow-up.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added, 1 site removed
    Show site
    • Central South University · Yuelucun, China
    Show 1 removed
    • Central South University · Yuelu, China
    Primary completion Dec 30, 2021→Dec 30, 2022
    Study completion Dec 30, 2021→Dec 30, 2022
    Enrollment 40→102
    Eligibility Revised
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedRelative telomere length (RTL)Time frame: baseline and 6 months follow-up.
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04326660
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Jul 20, 2020
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Nov 10, 2026

Study contacts

Jyu-Lin Chen, RN, PhD
principal investigator · University of California, San Francisco
Jia Guo, RN, PhD
principal investigator · Central South Univeristy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion